0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

THE USE OF SILVER ARSPHENAMIN IN THE TREATMENT OF WASSERMANN-FAST SYPHILIS

Irwin C. Sutton, M.D.
JAMA. 1923;80(9):622-623. doi:10.1001/jama.1923.26430360003009d.
Text Size: A A A
Published online

Many articles regarding the efficiency of silver arsphenamin have appeared in the literature since Kolle,1 in 1918, published the first of his series of reports. This much is established: it is an efficient spirocheticide; it is reasonably free from reactions, and it can be as conveniently administered as any other arsenical preparation.

The twenty-one cases reported were Wassermann fast. The patients, previous to the administration of the silver preparation, had had from four to thirty-four injections of arsphenamin and from thirteen to sixty-seven intramuscular injections of an insoluble mercury salt. The presence of a persistently positive Wassermann reaction in cases of intensive treatment is conceivably due to the continued activity of nests or foci of spirochetes resistant to medication. These foci are usually present in the cardiovascular and nervous systems. Detailed reexamination of these patients revealed evidence of activity that was unsuspected before treatment was instituted. These data are

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();